SCHEMBL2365482

SCHEMBL2365482

Nc1nc2cccc(-c3ccc(C=O)cc3)n2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.68
JAK1 P23458 8/20 0.62
EGLN2 Q96KS0 4/20 0.62
JAK3 P52333 2/20 0.51
JAK2 O60674 4/20 0.40
DYRK1B Q9Y463 2/20 0.40
PTK2 Q05397 1/20 0.40
DAPK3 O43293 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
FYN P06241 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
PDGFRB P09619 1/20 0.40
FGFR1 P11362 1/20 0.40
FLT3 P36888 1/20 0.40
MAPK8 P45983 1/20 0.40
GSK3B P49841 1/20 0.40
CDK9 P50750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3601961 0.83 NUDT1 (0.78) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL3200526 0.81 NUDT1 (0.76) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL2144054 0.81 NUDT1 (1.00) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL2250300 0.80 NUDT1 (0.73) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL22499606 0.80 NUDT1 (0.73) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL2363033 0.80 NUDT1 (0.73) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL3264207 0.79 NUDT1 (0.72) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL3262251 0.79 NUDT1 (0.71) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL15655016 0.78 NUDT1 (0.57) NUDT1JAK1EGLN2JAK3JAK2
SCHEMBL2730006 0.78 NUDT1 (0.69) NUDT1JAK1EGLN2JAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12042498-B2 Compound useful for the treatment of degenerative and inflammatory diseases ALFASIGMA S.P.A. (IT) 2024-07-23 US disclosed
US-20210369727-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2021-12-02 US disclosed
US-11000528-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2021-05-11 US disclosed
US-20200078365-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2020-03-12 US disclosed
US-10328081-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2019-06-25 US disclosed
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2019-02-19 US disclosed
US-20180000831-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2018-01-04 US disclosed
US-9707237-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2017-07-18 US disclosed
EP-3178819-A1 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS Galapagos NV (BE) 2017-06-14 EP disclosed
EP-2445911-B1 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS GALAPAGOS NV (BE) 2017-03-01 EP disclosed
US-8853240-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2014-10-07 US disclosed
EP-2361251-B1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2014-04-30 EP disclosed
US-20140100220-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV 2014-04-10 US disclosed
US-8563545-B2 Compound useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2013-10-22 US disclosed
US-20120142678-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV 2012-06-07 US disclosed
EP-2445911-A1 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS Galapagos N.V. (BE) 2012-05-02 EP disclosed
EP-2361251-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES Galapagos N.V. (BE) 2011-08-31 EP disclosed
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2010-12-30 US disclosed
WO-2010149769-A1 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS GALAPAGOS NV (BE) 2010-12-29 WO disclosed
WO-2010010190-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200078365-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-10328081-B2 Compound useful for the treatment of degenerative and inflammatory diseases IL6, JAK1, JAK2 NUDT1 3139/4885JAK1 2/4885EGLN2 2269/4885
US-10206907-B2 Compounds useful for the treatment of degenerative and inflammatory diseases TRAF6, TLR6, IL6 NUDT1 2363/4885JAK1 115/4885EGLN2 824/4885
US-20100331319-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-20140100220-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-20180000831-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-20120142678-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-12042498-B2 Compound useful for the treatment of degenerative and inflammatory diseases IL6, JAK1, BMP6 NUDT1 3774/4885JAK1 2/4885EGLN2 1539/4885
US-20210369727-A1 NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES IL6, JAK1, BMP6 NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885
US-11000528-B2 Compound useful for the treatment of degenerative and inflammatory diseases IL6, JAK1, BMP6 NUDT1 3774/4885JAK1 2/4885EGLN2 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.